glp-1 cardiovascular outcomes 2025 news Beyond GLP1: modulating multiple nutrient-stimulated hormone pathways to reduce risk SGLT2 inhibitors and GLP-1 receptor

Eric Topol (22:22): That's a very important point you're making because I think we conceive of these drugs as anti-inflammatory agents from these more diverse actions that we've just been reviewing

However, they have not all disappeared from the marketplace

But GLP-1s do not : Optimize metabolic efficiency Preserve lean muscle mass Support mitochondrial function Correct underlying insulin resistance And thats where problems begin

Available from: American Diabetes Association Professional Practice Committee

Most GLP-1 drugs are administered by injection, although oral versions are becoming more widely available

Yes, if obesity management is the priority and T2D is adequately controlled